Tagomics launches LiquiPath, a first-in-class cfDNA blood test for multi-organ drug safety monitoring
核心洞察
Tagomics Ltd. (搜索) has launched LiquiPath (搜索), a cross-species, multi-organ "liquid pathology" platform for non-invasive drug safety monitoring across preclinical, clinical, and on-market settings.
The platform combines Tagomics' Activace (搜索) epigenetic technology with cell-type-specific methylation atlases and deconvolution algorithms to trace circulating cell-free DNA to its tissue of origin from a single blood sample.
LiquiPath (搜索) is designed to enable earlier detection of subclinical toxicity, support adverse event prediction, and improve patient stratification, with an early access program now open to drug developers.
Tagomics Ltd. (搜索), a pioneering precision medicine company, has announced the launch of LiquiPath (搜索), a cross-species, multi-organ "liquid pathology" platform for non-invasive drug safety monitoring. Developed for use across preclinical studies, clinical development, and on-market surveillance, LiquiPath aims to give drug developers earlier and clearer insights into patient safety, with an early access program now open.
Therapy-induced toxicity remains a major barrier to successful drug development and safe patient care, contributing to trial failures, program delays, treatment interruptions, and potentially irreversible organ damage. Conventional safety monitoring still relies on non-specific biomarkers, imaging, and clinical symptoms, which often identify injury only after significant damage has occurred.
How LiquiPath Works
LiquiPath (搜索) combines Tagomics' epigenetic technology, Activace (搜索), with proprietary cell-type-specific methylation atlases and advanced deconvolution algorithms to trace circulating cell-free DNA (cfDNA) back to its tissue of origin. From a single blood sample, the platform is designed to enable sensitive, multi-tissue detection of treatment-related adverse effects.
In preclinical studies, the platform's multi-species, organ-agnostic capabilities have the potential to reduce reliance on histopathology and animal use, while supporting faster decision-making and toxicity-risk stratification. Clinically, it is designed to enable earlier detection of subclinical toxicity, support adverse event prediction, and improve patient stratification, ultimately helping more patients to benefit from life-saving therapies for longer.
Development Partners and Early Access
LiquiPath (搜索) is being developed through projects with several leading pharmaceutical partners, including AstraZeneca, across multiple therapeutic modalities and stages of development, supporting its broad applicability. Tagomics is now inviting additional partners to join its early access program and collaborate on priority use cases, validation studies, and future platform capabilities.
Leadership Perspective
Dr Jack Kennefick, CEO and Co-Founder of Tagomics, said: "Drug safety monitoring has remained largely unchanged for decades, with many current tools detecting damage only after it has occurred. LiquiPath (搜索) is designed to bring drug safety monitoring into the era of precision medicine, aiming to transform how toxicity is detected and understood across the drug development lifecycle. By reading tissue-specific cell-free DNA signals in blood, we believe the platform can help drug developers detect toxicity earlier and understand where injury is occurring. These insights are intended to support faster and better-informed decisions and help patients derive greater benefit from cutting-edge therapies."
Kennefick added that the launch, reflected in the company's new branding and website, "marks an important expansion of our capabilities beyond cancer detection and advances our mission of transforming precision medicine."